Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vudalimab - Xencor

Next Previous
Drug Profile

Vudalimab - Xencor

Alternative Names: PD-1 x CTLA-4 - Xencor; XmAb 717; XmAb-20717

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Gynaecological cancer; Prostate cancer; Urogenital cancer
  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 27 Feb 2024 Efficacy and adverse events data from a phase II trial in Prostate cancer released by Xencor
  • 13 Feb 2024 M.D. Anderson Cancer Center in collaboration with Xencor withdrew phase II RX-CROME trial prior to enrolment in Colorectal cancer (IV) (NCT05900648)
  • 27 Dec 2023 Phase-I/II clinical trials in Non-small cell lung cancer (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in USA (IV) (Xencor pipeline; December 2023) (NCT06173505)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top